1. Home
  2. NRIX vs SEDG Comparison

NRIX vs SEDG Comparison

Compare NRIX & SEDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • SEDG
  • Stock Information
  • Founded
  • NRIX 2009
  • SEDG 2006
  • Country
  • NRIX United States
  • SEDG Israel
  • Employees
  • NRIX N/A
  • SEDG N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • SEDG Semiconductors
  • Sector
  • NRIX Health Care
  • SEDG Technology
  • Exchange
  • NRIX Nasdaq
  • SEDG Nasdaq
  • Market Cap
  • NRIX 1.1B
  • SEDG 976.4M
  • IPO Year
  • NRIX 2020
  • SEDG 2015
  • Fundamental
  • Price
  • NRIX $11.88
  • SEDG $16.18
  • Analyst Decision
  • NRIX Strong Buy
  • SEDG Hold
  • Analyst Count
  • NRIX 17
  • SEDG 26
  • Target Price
  • NRIX $30.82
  • SEDG $26.62
  • AVG Volume (30 Days)
  • NRIX 879.4K
  • SEDG 2.4M
  • Earning Date
  • NRIX 04-14-2025
  • SEDG 05-07-2025
  • Dividend Yield
  • NRIX N/A
  • SEDG N/A
  • EPS Growth
  • NRIX N/A
  • SEDG N/A
  • EPS
  • NRIX N/A
  • SEDG N/A
  • Revenue
  • NRIX $54,549,000.00
  • SEDG $901,456,000.00
  • Revenue This Year
  • NRIX N/A
  • SEDG $23.36
  • Revenue Next Year
  • NRIX $3.20
  • SEDG $35.43
  • P/E Ratio
  • NRIX N/A
  • SEDG N/A
  • Revenue Growth
  • NRIX N/A
  • SEDG N/A
  • 52 Week Low
  • NRIX $11.38
  • SEDG $10.24
  • 52 Week High
  • NRIX $29.56
  • SEDG $73.60
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 29.28
  • SEDG 49.11
  • Support Level
  • NRIX $12.20
  • SEDG $15.55
  • Resistance Level
  • NRIX $13.10
  • SEDG $17.97
  • Average True Range (ATR)
  • NRIX 0.77
  • SEDG 1.16
  • MACD
  • NRIX -0.01
  • SEDG -0.13
  • Stochastic Oscillator
  • NRIX 14.33
  • SEDG 47.63

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About SEDG SolarEdge Technologies Inc.

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.

Share on Social Networks: